|
|
|
|
|
| Clinincal characteristics of Mycoplasma pneumonia in adults |
| WANG Chun-ting, XU Jun, ZHU Hua-dong, YU Xue-zhong |
| Department of Emergency Medicine, Peking Union Medical College Hospital, Beijing 100730, China |
|
|
|
|
Abstract Objective To emphasize extrapulmonary symptoms on Mycoplasma pneumonia in adults and evaluate clinical efficacy of primary antibiotic. Methods 29 cases with diagnosis of mycoplasma pneumonia from Peking Union Medical College hospital during 2010~2017 were analyzed. Of which, 12 patients treated with Moxifloxacin (Moxifloxacin group) and 17 patients treated with Azithromycin (Azithromycin group) initially. Results Almost patients presented with fever and cough, and extrapulmonary symptoms including hemolytic anemia, tympanitis, arthritis, myocarditis occurred in 7 patients(24.1%). Compared with Azithromycin group, Moxifloxacin group was easier access to clinical stability ［(3.6±3.3)d vs. (8.2±3.5)d, P=0.002］. 14 patients in Azithromycin group changed antibiotic to Moxifloxacin later because of persistent fever. And then the temperature of 14 patients got back to normal in(3.4±2.4)d after changing antibiotic. Conclusion Mycoplasma pneumonia not only present within pulmonary, but also ocurr extrapulmonary symptoms. When patients with community acquired pneumonia along with hemolytic anemia, tympanitis, arthritis, myocarditis etc, Mycoplasma pneumonia infection should be highly considered. Moxifloxacin is easier access to clinical stability.
|
|
|
|
Corresponding Authors:
XU Jun, E-mail： xujunfree@126.com
|
|
|
|
| ［1］Saraya T. Mycoplasma pneumoniae infection: Basics［J］.J Gen Fam Med, 2017, 18: 118-125.
［2］Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogensin community-acquired pneumonia［J］. Am J Respir Crit Care Med, 2007, 175(10): 1086-1093.
［3］刘又宁，陈民钧，赵铁梅，等.中国城市成人社区获得性肺炎665例病原学多中心调查［J］.中华结核和呼吸杂志， 2006， 27(1)：3-8.
［4］Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis［J］. Front Microbiol, 2016, 7: 23.
［5］Oishi T, Narita M, Ohya H, et al. Rhabdomyolysis associated with antimicrobial drug-resistant Mycoplasma pneumoniae［J］. Emerg Infect Dis, 2012, 18(5): 849-851.
［6］Martin RE, Bates JH. Atypical pneumonia［J］. Infect Dis Clin North Am, 1991, 5(3): 585-601.
［7］Morozumi M, Iwata S, Hasegawa K, et al． Increased macrolide resistance of Mycoplasma pneumonia in pediatric patients with community-acquired pneumonia［J］. Antimicrob Agents Chemother, 2008, 52(1): 348-350.
［8］尹玉东，曹彬，王辉，等. 北京地区成人社区获得性肺炎患者中肺炎支原体耐药情况的多中心调查［J］. 中华结核和呼吸杂志， 2013， 36(12): 954-958.
［9］中华医学会呼吸病学分会. 社区获得性肺炎诊断和治疗指南［J］. 中华结核和呼吸杂志， 2006， 29(10)： 651-655.
［10］中国医师协会急诊医师分会. 急诊成人社区获得性肺炎诊治专家共识（一）［J］.中国急救医学， 2011， 31(10)： 865-871.
［11］曲久鑫，谷丽，吴疆，等. 北京地区成年人社区获得性肺炎中肺炎支原体急性感染的调查［J］. 中华流行病学杂志， 2012， 33（5）： 545-546.
［12］Ferguson GD, Gadsby NJ, Henderson SS, et al. Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK［J］. J Med Microbiol, 2013, 62(Pt-12):1876-1882.
［13］Peuchant O, Menard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis［J］. J Antimicrob Chemother, 2009, 64(1): 52-58.
［14］Zheng X, Lee S, Selvarangan R, et al. Macrolide-Resistant Mycoplasma pneumoniae, United States［J］. Emerg Infect Dis, 2015, 21(8): 1470-1472.
［15］Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients［J］. Antimicrob Agents Chemother, 2013, 57(8): 4046-4049.
［16］Yu-Dong Yin, Rui Wang, Chao Zhuo, et al. Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study［J］. J Thorac Dis, 2017, 9(10): 3774-3781. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
